Can Lynparza Hold On As PARP Inhibitors Enter First-Line Prostate Cancer Market?

 
• By Alaric DeArment

AstraZeneca, Pfizer and Johnson & Johnson are presenting Phase III data for PARP inhibitors combined with anti-androgen drugs in first-line mCRPC, a potential blockbuster opportunity.

AZ Cambridge campus
AstraZeneca - along with Pfizer and J&J - presented Phase III PARP inhibitor data in first-line prostate cancer at ASCO GU • Source: Shutterstock

More from Anticancer

More from Therapy Areas